// App-Quantinova.ai

9571 : Factors predicting the use of immunotherapy for patients with advanced melanoma.

Researchers

Presenter

  • Richard Wayne Joseph

Principal Investigators

  • Alicia Shillington

  • Cynthia Macahilig

  • Scott J. Diede

  • Vaidehi Dave

  • Qing Harshaw

  • Frank Xiaoqing Liu

Medical Centers

  • Mayo Clinic, Jacksonville, FL

  • EPI-Q Inc., Oak Brook, IL

  • Medical Data Analytics, Parsippany, NJ

  • Merck & Co., Inc., Kenilworth, NJ

  • MDA, Parsippany, NJ

  • EPI-Q Inc., Oak Brook, IL

  • Merck & Co., Inc., North Wales, PA

Locations

  • United States

Companies

  • EPI-Q, Inc.

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Nivolumab

Outcome

  • N/A


Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final